Literature DB >> 35280060

Edith Pituskin1.   

Abstract

Entities:  

Year:  2022        PMID： 35280060      PMCID： PMC8849167     

Source DB:  PubMed          Journal:  Can Oncol Nurs J        ISSN： 1181-912X


× No keyword cloud information.
  39 in total

Review 1.  Bruton Tyrosine Kinase Inhibitors: Present and Future.

Authors:  Jan A Burger
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

2.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.

Authors:  Gillian Bethune; Drew Bethune; Neale Ridgway; Zhaolin Xu
Journal:  J Thorac Dis       Date:  2010-03       Impact factor: 2.895

3.  Impact of financial burden of cancer on survivors' quality of life.

Authors:  Kathleen M Fenn; Suzanne B Evans; Ruth McCorkle; Michael P DiGiovanna; Lajos Pusztai; Tara Sanft; Erin W Hofstatter; Brigid K Killelea; M Tish Knobf; Donald R Lannin; Maysa Abu-Khalaf; Nina R Horowitz; Anees B Chagpar
Journal:  J Oncol Pract       Date:  2014-05-27       Impact factor: 3.840

4.  Early palliative care for patients with metastatic non-small-cell lung cancer.

Authors:  Jennifer S Temel; Joseph A Greer; Alona Muzikansky; Emily R Gallagher; Sonal Admane; Vicki A Jackson; Constance M Dahlin; Craig D Blinderman; Juliet Jacobsen; William F Pirl; J Andrew Billings; Thomas J Lynch
Journal:  N Engl J Med       Date:  2010-08-19       Impact factor: 91.245

5.  The relationship between coping strategies, quality of life, and mood in patients with incurable cancer.

Authors:  Ryan D Nipp; Areej El-Jawahri; Joel N Fishbein; Justin Eusebio; Jamie M Stagl; Emily R Gallagher; Elyse R Park; Vicki A Jackson; William F Pirl; Joseph A Greer; Jennifer S Temel
Journal:  Cancer       Date:  2016-04-18       Impact factor: 6.860

6.  The experiences of Indigenous people with cancer in Saskatchewan: a patient-oriented qualitative study using a sharing circle.

Authors:  Tracey Carr; Lorna Arcand; Rose Roberts; Jennifer Sedgewick; Anum Ali; Gary Groot
Journal:  CMAJ Open       Date:  2020-12-10

7.  What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists.

Authors:  Gabrielle B Rocque; Aysha Rasool; Beverly R Williams; Audrey S Wallace; Soumya J Niranjan; Karina I Halilova; Yasemin E Turkman; Stacey A Ingram; Courtney P Williams; Andres Forero-Torres; Tom Smith; Smita Bhatia; Sara J Knight
Journal:  Oncologist       Date:  2019-03-14

8.  Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Authors:  G N Hortobagyi; S M Stemmer; H A Burris; Y S Yap; G S Sonke; S Paluch-Shimon; M Campone; K Petrakova; K L Blackwell; E P Winer; W Janni; S Verma; P Conte; C L Arteaga; D A Cameron; S Mondal; F Su; M Miller; M Elmeliegy; C Germa; J O'Shaughnessy
Journal:  Ann Oncol       Date:  2018-07-01       Impact factor: 32.976

9.  Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.

Authors:  Jennifer R Brown; Javid Moslehi; Susan O'Brien; Paolo Ghia; Peter Hillmen; Florence Cymbalista; Tait D Shanafelt; Graeme Fraser; Simon Rule; Thomas J Kipps; Steven Coutre; Marie-Sarah Dilhuydy; Paula Cramer; Alessandra Tedeschi; Ulrich Jaeger; Martin Dreyling; John C Byrd; Angela Howes; Michael Todd; Jessica Vermeulen; Danelle F James; Fong Clow; Lori Styles; Rudy Valentino; Mark Wildgust; Michelle Mahler; Jan A Burger
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

10.  Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.

Authors:  Jan A Burger; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Alessandra Tedeschi; Osnat Bairey; Peter Hillmen; Steven E Coutre; Stephen Devereux; Sebastian Grosicki; Helen McCarthy; David Simpson; Fritz Offner; Carol Moreno; Sandra Dai; Indu Lal; James P Dean; Thomas J Kipps
Journal:  Leukemia       Date:  2019-10-18       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.